Bictegravir
id:
bictegravir-308-13544228
title:
Bictegravir
text:
Bictegravir is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. In vitro and clinical results were presented by Gilead in the summer of 2016. In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection. The combination drug bictegravir/emtricitabine/tenofovir alafe
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Bictegravir
date created:
date modified:
2024-02-28T04:02:38Z
main entity:
{"identifier":"Q27270406","url":"https://www.wikidata.org/entity/Q27270406"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/f/f0/Bictegravir.svg","width":512,"height":205}
fields total:
13
integrity:
15